Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

FDA lets Direct Flow take on CoreValve

The FDA has allowed Direct Flow Medical to expand its pivotal trial to include high-risk patients, more centers and comparison with a commercially available transcatheter aortic valve replacement (TAVR) valve.

Thumbnail

Libidos & lipid-lowering drugs

A response to a query in the New York Times Well blog reviews the latest on sex on statins. Some research suggests statin use helps, some that it hurts and that if there is an issue, the patient and physician need to weigh pros and cons.

FDA allows less anticoagulation with On-X valve

The FDA expanded the labeling for a mechanical aortic valve by approving a lower International Normalized Ratio (INR) that is closer to an unmedicated range.

Medtronic acquires Diabeter, innovative diabetes care provider

Medtronic plc today announced its acquisition of Diabeter, an innovative, independent Netherlands-based diabetes clinic and research center dedicated to providing comprehensive and individualized care for children and young adults with diabetes.

Thumbnail

TAVR's growing presence

We are a quarter of the way into 2015 and TAVR already is jockeying to be the top story of the year.

Bayer HealthCare expands collaboration with Broad Institute of MIT and Harvard to develop therapies for cardiovascular disease

Bayer HealthCare (Bayer) has expanded its collaboration with the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies.

FDA clears CoreValve for valve-in-valve treatment

Medtronic snagged another victory for its CoreValve device with expanded FDA approval of its use in valve-in-valve procedures in inoperable and high-risk patients.

Thumbnail

Hospital volumes influence ECMO outcomes in adults

Annual hospital extracorporeal membrane oxygenation (ECMO) case volume may influence mortality, particularly in adults, according to an analysis of international registry data. 

Displaying 1145 - 1152 of 2332

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.